Novartis is pleased to announce that following a Priority Review, Health Canada has approved Kymriah™ (tisagenlecleucel/ CTL019) the...

Pre-clinical data has confirmed Noxopharm’s (ASX: NOX) experimental idronoxil anti-cancer drug can boost the killing effect of radiation...

A new cancer drug has proven safe and effective for pediatric patients with a rare tumour gene mutation. The study tested the safety and...

Young mice that received molecularly targeted therapies used to treat brain cancer in human patients sustained cognitive and behavioural...

The Senate on Thursday overwhelmingly passed legislation requiring the pharmaceutical industry to expend more resources on treatment for...

Patients who received doxorubicin for childhood cancers faced an increased risk for breast cancer and solid tumors later in life,...

While children over age 12 months with a common form of leukaemia have a 90 per cent chance of being cured, many babies do not survive....

Research from St. Jude Children's Research Hospital suggests that pediatric leukemia patients exposed to higher concentrations of the...

With a cure rate approaching 90 percent, acute lymphoblastic leukemia (ALL), the most common type of childhood cancer, is one of the big...

Today the drug is in clinical trials in 24 U.S. hospitals. Patient trials are aimed at assessing the drug's effectiveness against...